(Q33388240)

26 July 2017

A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas (English)

1 reference

26 July 2017

phase I clinical trial

0 references

phase II clinical trial

0 references

John A Butman

3

0 references

author name string

Teri N Kreisl

1

1 reference

26 July 2017

Svetlana Kotliarova

2

1 reference

26 July 2017

Paul S Albert

4

1 reference

26 July 2017

Lyndon Kim

5

1 reference

26 July 2017

Luna Musib

6

1 reference

26 July 2017

Donald Thornton

7

1 reference

26 July 2017

Howard A Fine

8

1 reference

26 July 2017

language of work or name

1 reference

22 January 2010

1 reference

26 July 2017

1 reference

26 July 2017

12

1 reference

26 July 2017

2

1 reference

26 July 2017

181-189

1 reference

Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation

26 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940576

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940576

Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940576

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940576

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940576

LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940576

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940576

Optimal two-stage designs for phase II clinical trials

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940576

Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940576

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

28 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOP042

Expression and distribution of vascular endothelial growth factor protein in human brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOP042

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOP042

Antiangiogenic effects of a protein kinase Cbeta-selective small molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOP042

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOP042

Synergistic antiglioma activity of radiotherapy and enzastaurin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOP042

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOP042

Venous thromboembolism and high grade gliomas.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940576

Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20150385

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20150385

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/NEUONC/NOP042

1 reference

26 July 2017

1 reference

26 July 2017

1 reference